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etter growth characteristics than IC-E122G and IC-D277A.
he reproduction of IC-E122G and IC-D277A in fasting ticks
as similar to that of control HA positive virus whereas
he titres of IC-D67G were signiﬁcantly lower (2.5-3 vs. 1-2
og10PFU/ml, respectively). In feeding ticks, the titre of IC-
122G increased approximately 1000-fold and IC-D277A and
C-D67G - approximately 300-fold, whereas for control virus
he increase was about 10-fold. Non-viraemic transmission
fﬁciency from infected to uninfected ticks was increased
y each individual substitution in nymphal I. ricinus (Figure
).
igure 1 Tick-to-tick transmission rate (clear bars) is
xpressed as the proportion of infected I.ricinus nymphs.
lack triangles show the average virus titres in individu-
lly infected recipient nymphs as determined by plaque
ssay.
Conclusion: We hypothesize that the mechanism
f adaptation of TBEV to its host utilizes the shift of
harge/hydrophobicity at several critical aminoacid
esidues exposed on the virion surface. This shift results in
ifferent biological consequences depending on the local-
sation of certain aminoacid residue. The results provide
aluable information concerning the maintenance in nature
nd the emergence of pathogenic variants of TBEV.
oi:10.1016/j.ijid.2010.02.1589
4.005
pre-exposure prophylactic for arenaviral hemorrhagic
ever in the pirital virus-Syrian golden hamster model
. Vela ∗, R. Stammen, J. Garver, S. Sarrazine
Battelle, Columbus, OH, USA
Background: Arenaviral infections in humans have the
apacity to lead to hemorrhagic fever and may be fatal.
upportive care and ribavirin remain the only options for
renaviral infections in humans; however, treatment is often
neffective because of the time frame before the disease is
ecognized. Pirital virus (PIRV) is a New World arenavirus
hat was isolated from the cotton rat (Sigmodon alstoni) in
he Municipality of Guanarito, Portuguesa State, Venezuela
n 1994. This virus is not associated with any form of disease
n humans and can be studied in a biosafety level 3 (BSL-
) laboratory environment; therefore, the development of
small animal model system is ideal for testing and/or
creening of vaccines and therapeutics against arenavirus
emorrhagic fever.
t
s
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Methods: Treated andmock-treated female Syrian golden
mplanted with telemetry units measuring temperature and
ctivity, were utilized to test the antiviral effects of the
ompound named BAT-V1. The animals were followed for
4 days post-challenge. Clinical signs of disease were mon-
tored. Temperatures and acitivty levels were recorded by
elemetry. Clinical chemistry, hematology, and coagulation
arameters were measured and viral titers in the tissues and
lood were analyzed.
Results: We demonstrate that PIRV infection in Syrian
olden hamsters leads to morbidity, fever, lethargy, hem-
rrhagic fever manifestations, viremia, and replication in
elect tissues and results in 100% mortality within 8 days
fter challenge. Treating hamsters with BAT-V1 prior to chal-
enge signiﬁcantly protected the animals from death, which
s important because survival of hamsters infected with PIRV
as not previously been reported. Abnormal temperatures,
ematology, clinical chemistry, and coagulation parameters
ssociated with PIRV infection in hamsters all rebounded to
ormal levels in the treated animals. Lower viremia and inhi-
ition of viral replication in select tissues were also observed
n treated animals when compared to mock-treated animals.
Conclusion: Results from this study demonstrate a BSL-
arenaviral hemorrhagic fever animal model that can be
tilized to test and screen multiple antivirals in a time
fﬁcient and cost effective manner. Additionally, the data
emonstrate pre-exposure protective efﬁcacy of an antiviral
gainst PIRV-induced hemorrhagic fever in the Syrian golden
amster model.
oi:10.1016/j.ijid.2010.02.1590
4.006
haracterization of a novel neutralizing monoclonal
ntibody that recognizes the fusion loop of Flavivirus
nvelope protein
. Deng1, G. Ji 2, Y. Kang2, T. Jiang1, J. Dai2, E. Qin1, Y.
uo2, C. Qin1,∗
Beijing Institute of Microbiology and Epidemiology, Bei-
ing, China
International Joint Cancer Institute, Second Military Med-
cal University, Shanghai, China
Background: Dengue, West Nile and yellow fever viruses
re major human pathogens that belong to the Flavivirus
enus, and cause large epidemics and deaths worldwide.
iven the lack of approved antiviral treatment, recombi-
ant monoclonal antibodies (MAbs) have been veriﬁed as
andidate for the treatment of ﬂavivirus infections.
Methods: A panel of MAbs against dengue 2 virus was
roduced according to the standard procedure. Indirect
mmunoﬂuorescence assay and ELISA were performed to
dentify the cross-reactivity against ﬂaviviruses. In vitro
ndin vivo experiments were performed to analyze the neu-
ralizing and protection proﬁles of a selected MAb against
engue and other ﬂavivirus. Epitope mapping and in vitro
inding inhibition assays were further carried out to charac-
erize this speciﬁc MAb.
Results: Plaque reduction neutralization test demon-
trated that MAb 2A10G6 was active to neutralize dengue
-4, yellow fever and West Nile viruses. In vivo protection
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expressed recombinant EDIII protein is antigenically active
and potentially useful for detecting antibodies against yel-
low fever virus.
doi:10.1016/j.ijid.2010.02.159314th International Congress on Infectious Diseases (ICID) Abs
experiments showed that mAb 2A10G6 protected sucking
mice from lethal dengue 1-4 viruses challenge in a dose-
dependent manner. Thus, we have established a novel
ﬂavivirus cross-reactive neutralizing mAb 2A10G6. Phage-
displayed random peptide library mapped the epitope of
mAb 2A10G6 to a common antigenic site within the highly
conserved N-terminal fusion loop peptide of ﬂavivirus enve-
lope protein. Functional assays conﬁrmed that mAb 2A10G6
bind with the fusion peptide and blocks infection primarily
at a step after viral attachment.
Conclusion: Together, these experiments deﬁne the char-
acteristics of a novel ﬂavivirus cross-reactive neutralizing
MAb 2A10G6 and make it a suitable candidate for human-
ization into a therapeutic antibody to treat severe ﬂavivirus
infections in human.
doi:10.1016/j.ijid.2010.02.1591
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Gene optimization for expression of Crimean-Congo
haemorrhagic fever viral nucleoprotein
R. Samudzi1,∗, F.J. Burt2
1 University of the Free State, Bloemfontein, Free State,
South Africa
2 UNIVERSITY OF THE FREE STATE, 9324, ZA, South Africa
Background: Crimean-Congo haemorrhagic fever (CCHF)
virus causes a severe and often fatal infection. The virus has
the propensity to cause nosocomial infections and hence a
rapid and sensitive diagnosis is important for isolation of the
patient for protection of health care workers and implemen-
tation of supportive therapy. Current serological diagnostic
assays are based on enzyme linked immunosorbent assays
(ELISA) or immunoﬂuorescence (IF) tests using inactivated
virus which necessitates biosafety level (BSL) 4 facilities for
preparation of reagents. The aim of the study was to pre-
pare a safe recombinant nucleoprotein (NP) and determine
its suitability for detection of antibody responses in survivors
of CCHF infection. To facilitate protein expression the gene
encoding the nucleoprotein was optimized for E.coli usage.
Methods: The CCHF nucleoprotein gene coding sequence
was submitted to GenScript (USA). OptimumGene software
was used to optimize codon usage, GC content, elimi-
nate polyadenylation sites and modify cis-acting sites. The
optimized gene was synthesized and the nucleoprotein
expressed in an E.coli bacterial expression system with
a His tag for puriﬁcation. CCHF antibody positive human
sera were tested in an ELISA using the recombinant NP
antigen.
Results: A direct ELISA was developed in which plates
were coated with the recombinant NP antigen and reacted
with convalescent human sera from conﬁrmed CCHF
patients. The antigen expressed from the optimized NP gene
was found to detect IgG antibodies against CCHF virus.
Conclusion: Recombinant proteins have been shown to
be safe, cost effective reagents that can be prepared for
biohazardous pathogens without the requirements of BSL
4 facilities. Optimization of the CCHF N gene was essen-
tial for high expression of soluble NP. The protein expressed
was shown to react against antibodies in convalescent CCHF
patients. A panel of serum samples from conﬁrmed patientsts e47
ill be used to determine the speciﬁcity and sensitivity of
he ELISA for diagnostic purposes.
oi:10.1016/j.ijid.2010.02.1592
4.008
reparation of antigenically active recombinant yellow
ever viral envelope domain III protein
. Smouse1,∗, F.J. Burt2
University of the Free State, Bloemfontein, Free State,
outh Africa
UNIVERSITY OF THE FREE STATE, 9324, ZA, South Africa
Background: Yellow fever virus belongs to the genus Fla-
ivirus, of the family Flaviviridae. It is a mosquito-borne
irus endemic in tropical regions of Africa and South Amer-
ca. Although an effective vaccine is available, the virus
emains a major public health threat, particularly in Africa
here vaccination is limited by poverty, civil wars and the
naccessibility of rural areas prone to outbreaks. It is a re-
merging pathogen with case-fatality rates that can exceed
0%. The diagnosis of infection and testing of the immune
tatus of vaccinees require reagents that are prepared in
iosafety level 3 and 4 facilities. The viral envelope pro-
ein plays an important role in eliciting antibodies and hence
erves as an ideal diagnostic and research tool for the detec-
ion of antibodies. The aim of the study was to compare
arious bacterial expression systems for the preparation of
recombinant yellow fever viral envelope protein for the
etection of antibodies against yellow fever in vaccinated
ndividuals.
Methods: The domain III region of the envelope (EDIII)
ene was ampliﬁed with primers identiﬁed using sequence
ata retrieved from GenBank. The EDIII gene was cloned
nto three different E.coli bacterial expression systems for
omparison of protein yield, solubility and suitablity in an
LISA. Proteins were all expressed with an N+ terminal His
ag for puriﬁcation. A direct ELISA was developed in which
he plates were coated with antigen and reacted with serum
amples from vaccinees.
Results: Each antigen was evaluated using serum samples
ollected from vaccinees and serological cross reactivity
f the antigen against heterologous ﬂaviviral antibody was
etermined using convalescent serum samples from patients
ith known ﬂaviviral infections, such as West Nile. Protein
ields varied signiﬁcantly between the different expression
ystems with higher yields and increased solubility obtained
rom expression at lower temperatures. Higher reactivity
as associated with homologous antibody.
Conclusion: Preliminary results suggest that bacterially
